Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences

Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences

NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI)
disorders and diseases, announced today that President and CEO Gary S. Jacob,
Ph.D., will be presenting a corporate overview at two healthcare conferences
at the Waldorf Astoria Hotel in New York this month.

  *15th Annual BIO CEO & Investor Conference, hosted by the Biotechnology
    Industry Organization (BIO), on Monday, February 11^th at 1:00 p.m. EST in
    the East Foyer
  *Leerink Swan Global Healthcare Conference on Wednesday, February 13^th at
    9:00 a.m. EST in the Metropolitan Suite

Live audio webcasts of both presentations will be available under the investor
relations section of Synergy's website at www.synergypharma.com. Replays of
the presentations will be available for 30 days afterward.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate, plecanatide, is a synthetic analog of the human
gastrointestinal hormone uroguanylin, and functions by activating the
guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy
completed a positive Phase I study of plecanatide in healthy volunteers, and
positive Phase IIa and Phase IIb/III clinical trials in patients with chronic
idiopathic constipation (CIC). Detailed positive findings from a recently
completed 948 patient CIC clinical will be presented at a major scientific
meeting this year. Synergy is also developing plecanatide for the treatment of
irritable bowel syndrome with constipation (IBS-C), having initiated the first
trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333,
is in clinical development to treat inflammatory bowel diseases, and has just
completed its first Phase I trial in healthy volunteers. More information is
available at http://www.synergypharma.com.

CONTACT: Media Contact: Janet Skidmore
         Office:  215-658-4915
         Mobile:  215-429-2917
         skidmorecomm@earthlink.net
        
         Investor Contact: Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924